Hwang Hee Sang, Sung Hyun-Jung, Kim Mee-Jeong, Yoon Dok Hyun, Park Chan-Sik, Huh Jooryung, Go Heounjeong
Departments of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Departments of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
Leuk Lymphoma. 2022 Dec;63(13):3072-3081. doi: 10.1080/10428194.2022.2113525. Epub 2022 Sep 27.
The clinical significance of extra copy (EC) genotypes of , , and have not been fully elucidated. We evaluated the EC and translocation statuses of , , and in 190 diffuse large B-cell lymphoma (DLBCL) cases using fluorescence hybridization. EC genotype was sub-classified according to copy number-gained tumor cell ratio (EC1, >20% but ≤50%; EC2, >50%). Only the -EC groups, not -EC or -EC groups, displayed significantly increased immunoreactivity of the corresponding protein. Moreover, the -EC2 group was significantly associated with poor overall survival (OS) and progression-free survival (PFS) in a 147 R-CHOP-treated patient subset, which was also statistically significant as per the multivariate survival analysis for PFS. No significant differences in the survival of , , concurrent , , or triple EC groups were observed. -EC may contribute to increased BCL-2 protein expression and serve as a predictor of treatment outcomes in DLBCL.
、和的额外拷贝（EC）基因型的临床意义尚未完全阐明。我们使用荧光原位杂交技术评估了190例弥漫性大B细胞淋巴瘤（DLBCL）病例中的、和的EC及易位状态。EC基因型根据获得拷贝数的肿瘤细胞比例进行亚分类（EC1，>20%但≤50%；EC2，>50%）。只有-EC组，而非-EC或-EC组，显示出相应蛋白的免疫反应性显著增加。此外，在147例接受R-CHOP治疗的患者亚组中，-EC2组与较差的总生存期（OS）和无进展生存期（PFS）显著相关，根据PFS的多变量生存分析，这也具有统计学意义。在、、同时存在、或三重EC组的生存情况中未观察到显著差异。-EC可能有助于增加BCL-2蛋白表达，并可作为DLBCL治疗结果的预测指标。
